Breast Cancer and Osteoporosis - Management of Cancer Treatment-Induced Bone Loss in Postmenopausal Women with Breast Cancer

Abstract

The incidence of breast cancer (BC) in postmenopausal women is continuously rising. Due to early diagnosis and various treatment designs, the long-term clinical outcome has improved. Frequent settings are chemotherapy as well as endocrine treatment. Both have proven to interfere with bone health resulting in cancer treatment-induced bone loss (CTIBL). Whereas chemotherapy is associated with increased bone resorption, aromatase inhibitor (AI) therapy reduces residual estrogen and is associated with decreased bone mineral density. Independent of the AI administered, the loss of bone mineral density is twice as high compared to healthy postmenopausal women. As a consequence of CTIBL, both chemotherapy and AI treatment can lead to a significantly increased fracture risk. Therefore, several guidelines have emerged for the management of CTIBL in women with BC, including strategies to identify and treat those at high risk for fractures. Further research on tracking guideline adherence examining the feasibility and practicability of guideline implementation to bridge the gap between determined scientific best evidence and applied best practice is needed to adjust these guidelines in the future.

Long Chain Omega-3 Polyunsaturated Fatty Acid Supplementation Protects Against Adriamycin and Cyclophosphamide Chemotherapy-Induced Bone Marrow Damage in Female Rats

“…However, women receiving combination treatment experienced more adverse effects. Chemotherapeutics such as taxane, adriamycin, 5-fluorouracil, cyclophosphamide, methotrexate, and cisplatin are known to cause an increase in bone resorption independent of bone metastasis and a deterioration in bone structure [ 17 ]. Adriamycin is a common anthracycline agent that is used widely in treating both early and late stage metastatic breast cancer.…”

Bone loss during neoadjuvant/adjuvant chemotherapy for�early stage breast cancer: A retrospective cohort study

“…Despite the large doses given over a relatively short time period, a recent study found no relation between prednisolone dose and BMD change (8). Actually, the BMD had increased four months after adjuvant chemotherapy, contrary to what other studies have shown (3,(8)(9)(10).…”

Opportunistic use of chest CT for screening osteoporosis and predicting the risk of incidental fracture in breast cancer patients: A retrospective longitudinal study

“…Postmenopausal women with breast cancer frequently experience cancer treatment-induced bone loss [ 2 , 17 ]. Cody et al suggested that younger breast cancer survivors are also at higher risk of osteoporosis compared to cancer-free women [ 18 ].…”